| Filed On | Filing |
|---|---|
| 11 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +8 more
An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, a... |
| 29 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
a private limited company organized under the laws of England and Wales |
| 25 Mar 2026 |
8-K: Results of Operations and Financial Condition
$49.1 million global net product revenue of EKTERLY® (sebetralstat) for the eight months ended December 31, 2025 |
| 08 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
KalVista Pharmaceuticals Corporate Overview January 2026 Exhibit 99.2 |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
US launch of EKTERLY® gaining strong momentum with $13.7 million in net product revenue for the third quarter |
| 06 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
This Indemnity Agreement, dated as of _____________, [YEAR] is made by and between KalVista Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and _____________, a director, officer or key employee of the Company or one of th... |
| 02 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders +1 more
FRAMINGHAM, Mass. & Salisbury, England, October 2, 2025 – KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the appointment of Bethany L. Sensenig to its Board of Directors, effective as of October 1, 2025. Ms. Sensenig was a... |
| 29 Sep 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
INDENTURE, dated as of September 29, 2025, between KalVista Pharmaceuticals, Inc., a Delaware corporation (the “Company”, as more fully set forth in Section 1.01), and U.S. Bank Trust Company, National Association, a national banking ass... |
| 11 Sep 2025 |
8-K: Results of Operations and Financial Condition
-EKTERLY® now approved in the US and UK; first and only oral on-demand therapy for acute attacks of hereditary angioedema- |
| 21 Aug 2025 |
8-K: Other Events
KalVista Pharmaceuticals, Inc. (the “Company”) has set June 18, 2026 as the date of the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). The time and location of the Annual Meeting will be set forth in the Compa... |
| 10 Jul 2025 |
8-K: Results of Operations and Financial Condition
– Received FDA approval of EKTERLY® (sebetralstat)—the first and only oral on-demand |
| 07 Jul 2025 |
8-K: Regulation FD Disclosure; Other Events
U.S. FDA Approval of EKTERLY® (sebetralstat) July 7, 2025 Exhibit 99.2 |
| 12 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 08 Apr 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
KalVista Pharmaceuticals Enters into Licensing Agreement with Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan |
| 17 Mar 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. |
| 12 Mar 2025 |
8-K: Results of Operations and Financial Condition
–Announced seventh regulatory application submission and secured orphan drug designation for sebetralstat in Japan for hereditary angioedema– |
| 16 Dec 2024 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Cambridge, MA and Salisbury, England, December 16, 2024 – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO). Mr. Ledell is an accomplished public compan... |
| 05 Dec 2024 |
8-K: Results of Operations and Financial Condition
–Continuing to build commercial infrastructure; on track for potential sebetralstat launch in Q2 2025– |
| 26 Nov 2024 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Cambridge, Mass., and Salisbury, England, November 26, 2024 – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company’s Board of Directors, effective immediately. Dr. Re... |
| 04 Nov 2024 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
Introductory. KalVista Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A hereto (the “Underwriters”) 5,500,000 shares of its common stock, $0.001 par... |
Loading...